Your browser is no longer supported. Please, upgrade your browser.
Settings
CNAT Conatus Pharmaceuticals Inc. daily Stock Chart
CNAT [NASD]
Conatus Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.61 Insider Own3.67% Shs Outstand34.33M Perf Week-63.23%
Market Cap58.70M Forward P/E- EPS next Y-0.17 Insider Trans0.00% Shs Float29.15M Perf Month-66.99%
Income-18.50M PEG- EPS next Q-0.15 Inst Own32.80% Short Float11.39% Perf Quarter-64.23%
Sales35.00M P/S1.68 EPS this Y53.60% Inst Trans-9.38% Short Ratio3.96 Perf Half Y-61.74%
Book/sh0.55 P/B3.11 EPS next Y72.10% ROA-26.00% Target Price12.00 Perf Year-56.38%
Cash/sh1.44 P/C1.18 EPS next 5Y38.00% ROE-84.00% 52W Range1.52 - 7.95 Perf YTD-62.99%
Dividend- P/FCF- EPS past 5Y41.10% ROI-42.60% 52W High-79.75% Beta2.35
Dividend %- Quick Ratio2.40 Sales past 5Y- Gross Margin- 52W Low5.92% ATR0.54
Employees33 Current Ratio2.40 Sales Q/Q-19.80% Oper. Margin-53.30% RSI (14)20.34 Volatility18.09% 10.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.00% Profit Margin-52.80% Rel Volume3.81 Prev Close1.71
ShortableYes LT Debt/Eq0.83 EarningsNov 01 AMC Payout- Avg Volume838.43K Price1.61
Recom2.00 SMA20-63.95% SMA50-65.78% SMA200-65.58% Volume455,905 Change-5.85%
Dec-06-18Downgrade Stifel Buy → Hold
Feb-08-18Initiated ROTH Capital Buy $20
Nov-02-17Reiterated H.C. Wainwright Buy $18 → $17
Mar-16-17Reiterated Stifel Buy $7 → $9
Dec-20-16Reiterated Stifel Buy $5 → $7
Dec-20-16Reiterated H.C. Wainwright Buy $9 → $18
Nov-09-16Reiterated Stifel Buy $6 → $5
Jul-01-16Resumed ROTH Capital Buy
Nov-05-15Reiterated Stifel Buy $11 → $9
Sep-22-15Initiated H.C. Wainwright Buy $15
Apr-28-15Initiated Brean Capital Buy $13
Mar-17-15Resumed ROTH Capital Buy $15
Mar-12-15Reiterated Stifel Buy $13 → $11
Jan-09-15Reiterated ROTH Capital Buy $19 → $12
Oct-21-14Initiated MLV & Co Buy $16
Aug-14-14Reiterated Stifel Buy $14 → $13
Aug-19-13Initiated Stifel Buy $16
Dec-07-18 08:04AM  The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut Benzinga -11.86%
Dec-06-18 02:51PM  Conatus' Emricasan Misses Primary Endpoint in Mid-Stage Study Zacks -56.89%
02:13PM  Shares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint MarketWatch
07:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixis ACCESSWIRE
Dec-05-18 07:30AM  Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis GlobeNewswire
Nov-16-18 10:42AM  When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable? Simply Wall St.
07:50AM  Investor Expectations to Drive Momentum within 2U, Broadwind Energy, Nuverra Environmental Solutions, Ability, ContraFect, and Conatus Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Nov-14-18 08:46AM  Do Options Traders Know Something About Conatus (CNAT) Stock We Don't? Zacks -6.67%
Nov-09-18 05:28PM  Edited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents -6.81%
Nov-08-18 07:30AM  Conatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meeting GlobeNewswire +8.73%
Nov-05-18 07:00AM  Todays Research Reports on Stocks to Watch: Conatus Pharmaceuticals and Titan Pharmaceuticals ACCESSWIRE
Nov-02-18 12:30PM  Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates Zacks +19.63%
07:30AM  Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates Zacks
05:03AM  Conatus: 3Q Earnings Snapshot Associated Press
Nov-01-18 04:05PM  Conatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updates GlobeNewswire
Oct-25-18 07:30AM  Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results GlobeNewswire
Oct-11-18 08:51AM  Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock Zacks
Oct-02-18 04:05PM  Conatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meeting GlobeNewswire
Sep-25-18 08:00AM  Conatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Target ACCESSWIRE -7.70%
Sep-20-18 07:30AM  Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension GlobeNewswire +17.37%
Sep-19-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics ACCESSWIRE
07:30AM  Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
Sep-18-18 10:50AM  Who Owns Most Of Conatus Pharmaceuticals Inc (NASDAQ:CNAT)? Simply Wall St. +12.98%
Aug-31-18 09:58AM  Options Traders Expect Huge Moves in Conatus Pharmaceuticals (CNAT) Stock Zacks
09:49AM  Conatus (CNAT) Up 36.2% Since Last Earnings Report: Can It Continue? Zacks
Aug-29-18 07:30AM  Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference GlobeNewswire
Aug-23-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE +6.78%
Aug-03-18 05:14PM  Edited Transcript of CNAT earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-18 11:47AM  Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks
Aug-01-18 08:20PM  Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:15PM  Conatus: 2Q Earnings Snapshot Associated Press
04:05PM  Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates GlobeNewswire
Jul-30-18 12:15PM  What's in the Cards for Conatus (CNAT) This Earnings Season? Zacks
Jul-25-18 04:05PM  Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results GlobeNewswire
Jul-02-18 07:30AM  Conatus Pharmaceuticals Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis GlobeNewswire +6.78%
Jun-14-18 09:23AM  NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
Jun-01-18 10:20AM  Why Is Conatus Pharmaceuticals (CNAT) Up 4.1% Since Its Last Earnings Report? Zacks
May-03-18 11:58AM  Conatus' (CNAT) Q1 Loss In Line, Revenues Beat Estimates Zacks -5.43%
May-02-18 06:22PM  Conatus: 1Q Earnings Snapshot Associated Press
04:05PM  Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates GlobeNewswire
Apr-30-18 07:30AM  Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension GlobeNewswire
Apr-27-18 11:50AM  What's in the Cards for Conatus (CNAT) This Earnings Season? Zacks
Apr-25-18 04:05PM  Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results GlobeNewswire +9.70%
Apr-18-18 07:30AM  Conatus Pharmaceuticals IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo GlobeNewswire
Apr-11-18 10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
07:00AM  Wired News Conatus to Demonstrate Impact of Pan-caspase Inhibitor IDN-7314 in Reducing Inflammation and Liver Injury in Mouse Model of PSC at EASL Annual Meeting ACCESSWIRE
Apr-09-18 07:30AM  Conatus Pharmaceuticals Announces Upcoming Oral Presentation at EASL Annual Meeting GlobeNewswire
Apr-06-18 08:36AM  Are Options Traders Betting on a Big Move in Conatus (CNAT) Stock? Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Intercept Pharmaceuticals and Conatus Pharmaceuticals ACCESSWIRE
Apr-05-18 10:37AM  Conatus' Emricasan Fails in Phase II Study, Shares Sink Zacks -31.45%
08:32AM  Heres Whats Moving Conatus And Paratek Market Exclusive
08:20AM  Todays Research Reports on Trending Tickers: Conatus Pharmaceuticals and bluebird bio ACCESSWIRE
Apr-04-18 05:21PM  What Spooked Conatus Pharmaceuticals (CNAT) Investors This Evening SmarterAnalyst
05:05PM  Conatus Pharma shares fall on liver-drug study data MarketWatch
04:05PM  Conatus Pharmaceuticals Announces Top-line Results from Phase 2b POLT-HCV-SVR Clinical Trial GlobeNewswire
Mar-08-18 10:37AM  Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss Zacks +9.01%
Mar-07-18 04:35PM  Conatus reports 4Q loss Associated Press
04:05PM  Conatus Pharmaceuticals Reports 2017 Financial Results and Program Updates GlobeNewswire
12:15PM  Conatus Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
09:48AM  Conatus Pharmaceuticals Q4 Earnings Outlook Benzinga
Mar-05-18 10:36AM  What's in Store for Conatus (CNAT) This Earnings Season? Zacks +10.29%
08:30AM  Todays Research Reports on Trending Tickers: Conatus Pharmaceuticals and Sarepta Therapeutics ACCESSWIRE
07:30AM  Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences GlobeNewswire
Mar-02-18 12:03PM  When Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Breakeven? Simply Wall St. +17.92%
Feb-28-18 07:30AM  Conatus Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Feb-12-18 07:30AM  Conatus Pharmaceuticals to Host Expert Call on Unmet Need in HCV-SVR Patients GlobeNewswire
Feb-05-18 07:30AM  Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts and Strategic Initiatives at Upcoming Investor Events GlobeNewswire -6.00%
Jan-24-18 04:23PM  Was Conatus Pharmaceuticals Incs (NASDAQ:CNAT) Earnings Growth Better Than The Industrys? Simply Wall St. -9.96%
Nov-07-17 07:30AM  Conatus to Present at Stifel Healthcare Conference GlobeNewswire
Nov-02-17 10:19AM  Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss Zacks -5.54%
Nov-01-17 06:20PM  Conatus reports 3Q loss Associated Press
04:05PM  Conatus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Program Updates GlobeNewswire
09:35AM  Conatus Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Oct-27-17 01:11PM  What's in Store for Conatus (CNAT) This Earnings Season? Zacks +5.25%
Oct-25-17 07:30AM  Conatus Pharmaceuticals to Report Third Quarter 2017 Financial Results GlobeNewswire
Oct-20-17 10:22AM  Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU Zacks
08:00AM  Conatus Pharmaceuticals Announces Poster Presentation at AASLD Annual Meeting GlobeNewswire
Oct-19-17 09:36AM  Conatus Entrusts Keith W. Marshall With Key Management Roles Zacks
Oct-18-17 04:05PM  EMA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC GlobeNewswire
Sep-28-17 09:23AM  Will Conatus Liver Disease Candidate Drive Long-Term Growth? Zacks
Sep-19-17 01:53PM  Hedge fund manager shuts firm to explore run for Connecticut governor Reuters
Sep-08-17 08:26AM  Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue? Zacks
Aug-31-17 04:05PM  Conatus Pharmaceuticals Appoints Keith W. Marshall as Executive Vice President, Chief Operating Officer and Chief Financial Officer GlobeNewswire
Aug-29-17 04:05PM  Conatus to Present at Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-21-17 05:47PM  Will Conatus Key Candidate Emricasan Drive Long-Term Growth? Zacks
Aug-14-17 04:05PM  Conatus Announces Completion of Enrollment in ENCORE-NF Phase 2b Clinical Trial of Emricasan in Patients with NASH Fibrosis GlobeNewswire
Aug-03-17 04:41PM  Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Zacks -7.72%
01:05AM  Conatus reports 2Q loss Associated Press
Aug-02-17 04:05PM  Conatus Pharmaceuticals Reports Second Quarter 2017 Financial Results and Program Updates GlobeNewswire
10:00AM  Investor Network: Conatus Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Jul-26-17 04:05PM  Conatus Pharmaceuticals to Report Second Quarter 2017 Financial Results GlobeNewswire
10:29AM  What's in Store for Conatus (CNAT) this Earnings Season? Zacks
Jul-07-17 08:50AM  Why Conatus Pharma Wins With Newest Licensing Agreement 24/7 Wall St. +5.34%
Jul-06-17 04:05PM  Conatus Announces Effectiveness of Exclusive License for Global Development and Commercialization of Emricasan with Receipt of $7 Million Payment GlobeNewswire
Jun-29-17 12:48PM  H.C. Wainwright Bullish on Conatus Pharmaceuticals Inc (CNAT) on Back of Orphan Drug Designation for IDN-7314 SmarterAnalyst +10.71%
Jun-27-17 10:52AM  Company News for June 27, 2017 Zacks
08:50AM  Conatus's PSC Candidate Gets Orphan Designation in the U.S. Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals Accesswire
Jun-26-17 07:00AM  FDA Grants Conatus Orphan Drug Designation for IDN-7314 for the Treatment of PSC GlobeNewswire +9.61%
Jun-16-17 07:00AM  Conatus Pharmaceuticals Announces Poster Presentation at International Liver Cell Conference GlobeNewswire
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company has collaboration agreement with Novartis to conduct three Phase IIb clinical trials Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mento Steven JPresident, CEO & DirectorMay 04Option Exercise0.9960,00059,40060,000May 07 07:46 PM
Spada Alfred P.EVP, R&D and CSOFeb 27Option Exercise1.2412,12115,03012,121Mar 01 04:08 PM